The latent period between pembrolizumab exposure and onset of symptoms inSJS varies from 7 to 140 days.8 In histologic analyses of adverse cutaneous induced by anti-PD-1 therapy,there is evidence of accumulation of CD8+ T-cell at the dermoepidermal junction andCD8+ T-cell exocytosis into the epidermis with apoptotic keratinocytes.2 These features are also observed in SJS.2 In addition, gene expression profiles from skin lesions caused by anti-PD-1therapy and SJS has similarities.2,8 These findings suggests thatanti-PD-1 antibody can induce SJS-like adverse reactions.2 Here, CD8A is linked to Schwartz-Jampel syndrome.